

Vera J Suman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7008510/publications.pdf>

Version: 2024-02-01

53
papers

2,728
citations

236925

25
h-index

189892

50
g-index

58
all docs

58
docs citations

58
times ranked

5456
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 1526-1527.	1.5	7
2	Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center. <i>Cancer</i> , 2022, 128, 1038-1047.	4.1	5
3	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	5.2	9
4	A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-13.	2.4	3
5	Evaluation of Sensitivity to Endocrine Therapy Index (SET _{2,3}) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). <i>Clinical Cancer Research</i> , 2022, 28, 3287-3295.	7.0	6
6	Future Directions in Maintenance Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2261.	2.4	8
7	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	7.0	7
8	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
9	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq1 1 0.784314 rgBT /Over 1627-1632.	2.5	16
10	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 51.	5.0	11
11	Evidence-based guidelines for managing patients with primary ER+ HER2 \hat{a} breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020, 6, 21.	5.2	42
12	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1414-1424.	2.0	5
13	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor \hat{a} . <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	7.0	17
14	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. <i>Genetics in Medicine</i> , 2019, 21, 71-80.	2.4	52
15	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 31-38.	2.3	15
16	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. <i>Journal of Clinical Oncology</i> , 2019, 37, 1982-1983.	1.6	17
17	Comparison of ^{99m}Tc -Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>American Journal of Roentgenology</i> , 2019, 213, 932-943.	2.2	15
18	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. <i>JAMA Oncology</i> , 2019, 5, 45.	7.1	16

#	ARTICLE	IF	CITATIONS
19	Commentary on "ceels posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale. <i>Leukemia</i> , 2019, 33, 565-566.	7.2	2
20	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. <i>Oncotarget</i> , 2019, 10, 3924-3930.	1.8	11
21	Comparison of a Medical-Grade Monitor vs Commercial Off-the-Shelf Display for Mitotic Figure Enumeration and Small Object (<i>Helicobacter pylori</i>) Detection. <i>American Journal of Clinical Pathology</i> , 2018, 149, 181-185.	0.7	14
22	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. <i>Journal of Clinical Investigation</i> , 2018, 128, 2376-2388.	8.2	134
23	ER β -mediated induction of cystatins results in suppression of TGF β signaling and inhibition of triple-negative breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9580-E9589.	7.1	47
24	Update on the role of lenalidomide in patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 175-190.	2.5	42
25	Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. <i>Oncotarget</i> , 2018, 9, 30268-30278.	1.8	49
26	Patterns of failure following the excision of inâ€transit lesions in melanoma and the influence of excisional margins. <i>Journal of Surgical Oncology</i> , 2018, 118, 606-613.	1.7	8
27	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq1 1 0.784314#rgBT /Overlock		
28	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	1.6	254
29	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4506-4514.	3.6	86
30	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7288-7300.	7.0	29
31	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	61
32	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III<i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	7.0	66
33	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	9.4	58
34	Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2017, 57, 220-225.	2.3	40
35	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	5.0	53
36	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 91803-91816.	1.8	23

#	ARTICLE	IF	CITATIONS
37	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3391-3400.	1.6	58
38	A comprehensive analysis of breast cancer microbiota and host gene expression. <i>PLoS ONE</i> , 2017, 12, e0188873.	2.5	111
39	ER β inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 96506-96521.	1.8	35
40	Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. <i>Biomolecules</i> , 2016, 6, 31.	4.0	9
41	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	4.1	37
42	Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. <i>Journal of the American College of Surgeons</i> , 2016, 222, 253-260.	0.5	16
43	Status of the Regional Nodal Basin Remains Highly Prognostic in Melanoma Patients with In-Transit Disease. <i>Journal of the American College of Surgeons</i> , 2016, 223, 77-85e1.	0.5	15
44	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12498.	12.8	69
45	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
46	Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1017-1023.	2.0	20
47	Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2509-2515.	1.6	59
48	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	37
49	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015, 126, 375-375.	1.4	19
50	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	1.6	771
51	Risk factors for primary central nervous system lymphoma. , 1998, 82, 975-982.		25
52	Risk factors for primary central nervous system lymphoma. <i>Cancer</i> , 1998, 82, 975-982.	4.1	1
53	Brain metastases from colorectal carcinoma: The long term survivors. <i>Cancer</i> , 1996, 78, 711-716.	4.1	133